198 related articles for article (PubMed ID: 32732977)
1. The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients.
Kinjo T; Kitaguchi Y; Droma Y; Yasuo M; Wada Y; Ueno F; Ota M; Hanaoka M
Sci Rep; 2020 Jul; 10(1):12811. PubMed ID: 32732977
[TBL] [Abstract][Full Text] [Related]
2. Association between plasma sRAGE and emphysema according to the genotypes of AGER gene.
Sin S; Lim MN; Kim J; Bak SH; Kim WJ
BMC Pulm Med; 2022 Feb; 22(1):58. PubMed ID: 35144588
[TBL] [Abstract][Full Text] [Related]
3. The Ser82 RAGE Variant Affects Lung Function and Serum RAGE in Smokers and sRAGE Production In Vitro.
Miller S; Henry AP; Hodge E; Kheirallah AK; Billington CK; Rimington TL; Bhaker SK; Obeidat M; Melén E; Merid SK; Swan C; Gowland C; Nelson CP; Stewart CE; Bolton CE; Kilty I; Malarstig A; Parker SG; Moffatt MF; Wardlaw AJ; Hall IP; Sayers I
PLoS One; 2016; 11(10):e0164041. PubMed ID: 27755550
[TBL] [Abstract][Full Text] [Related]
4. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.
Cheng DT; Kim DK; Cockayne DA; Belousov A; Bitter H; Cho MH; Duvoix A; Edwards LD; Lomas DA; Miller BE; Reynaert N; Tal-Singer R; Wouters EF; Agustí A; Fabbri LM; Rames A; Visvanathan S; Rennard SI; Jones P; Parmar H; MacNee W; Wolff G; Silverman EK; Mayer RJ; Pillai SG;
Am J Respir Crit Care Med; 2013 Oct; 188(8):948-57. PubMed ID: 23947473
[TBL] [Abstract][Full Text] [Related]
5. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis.
Yamaguchi K; Iwamoto H; Horimasu Y; Ohshimo S; Fujitaka K; Hamada H; Mazur W; Kohno N; Hattori N
Respirology; 2017 Jul; 22(5):965-971. PubMed ID: 28198072
[TBL] [Abstract][Full Text] [Related]
6. Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis.
Manichaikul A; Sun L; Borczuk AC; Onengut-Gumuscu S; Farber EA; Mathai SK; Zhang W; Raghu G; Kaufman JD; Hinckley-Stukovsky KD; Kawut SM; Jelic S; Liu W; Fingerlin TE; Schwartz DA; Sell JL; Rich SS; Barr RG; Lederer DJ
Ann Am Thorac Soc; 2017 May; 14(5):628-635. PubMed ID: 28248552
[TBL] [Abstract][Full Text] [Related]
7. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia.
Aslan EI; Ozkara G; Kilicarslan O; Ser OS; Bostan C; Yildiz A; Diren Borekcioglu A; Ozturk O; Kucukhuseyin O; Yilmaz Aydogan H
Gene; 2024 Jul; 916():148450. PubMed ID: 38588932
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population.
Xu L; Bian W; Gu XH; Shen C
Kaohsiung J Med Sci; 2017 Mar; 33(3):124-129. PubMed ID: 28254114
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema.
Cornwell WD; Kim C; Lastra AC; Dass C; Bolla S; Wang H; Zhao H; Ramsey FV; Marchetti N; Rogers TJ; Criner GJ
Biomarkers; 2019 May; 24(3):232-239. PubMed ID: 30411980
[No Abstract] [Full Text] [Related]
10. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.
Miniati M; Monti S; Basta G; Cocci F; Fornai E; Bottai M
Respir Res; 2011 Mar; 12(1):37. PubMed ID: 21450080
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in the receptor for advanced glycation end products (RAGE) gene were associated with circulating soluble RAGE level but not with renal function among Asians with type 2 diabetes: a genome-wide association study.
Lim SC; Dorajoo R; Zhang X; Wang L; Ang SF; Tan CSH; Yeoh LY; Ng XW; Li N; Su C; Liu S; Wong MDS; Low KMS; Yao AO; Babitha J; Fun S; Zhou S; Lee SBM; Tang WE; Tavintharan S; Sum CF; Liu JJ
Nephrol Dial Transplant; 2017 Oct; 32(10):1697-1704. PubMed ID: 27448675
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
Pratte KA; Curtis JL; Kechris K; Couper D; Cho MH; Silverman EK; DeMeo DL; Sciurba FC; Zhang Y; Ortega VE; O'Neal WK; Gillenwater LA; Lynch DA; Hoffman EA; Newell JD; Comellas AP; Castaldi PJ; Miller BE; Pouwels SD; Hacken NHTT; Bischoff R; Klont F; Woodruff PG; Paine R; Barr RG; Hoidal J; Doerschuk CM; Charbonnier JP; Sung R; Locantore N; Yonchuk JG; Jacobson S; Tal-Singer R; Merrill D; Bowler RP
Respir Res; 2021 Apr; 22(1):127. PubMed ID: 33906653
[TBL] [Abstract][Full Text] [Related]
13. The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease.
Sharma A; Kaur S; Sarkar M; Sarin BC; Changotra H
Clin Rev Allergy Immunol; 2021 Apr; 60(2):244-258. PubMed ID: 33170477
[TBL] [Abstract][Full Text] [Related]
14. Implication of RAGE Polymorphic Variants in COPD Complication and Anti-COPD Therapeutic Potential of sRAGE.
Malik P; Hoidal JR; Mukherjee TK
COPD; 2021 Dec; 18(6):737-748. PubMed ID: 34615424
[TBL] [Abstract][Full Text] [Related]
15. The Gly82Ser polymorphism in the receptor for advanced glycation endproducts increases the risk for coronary events in the general population.
Grauen Larsen H; Sun J; Sjögren M; Borné Y; Engström G; Nilsson P; Orho-Melander M; Goncalves I; Nilsson J; Melander O; Schiopu A
Sci Rep; 2024 May; 14(1):11567. PubMed ID: 38773223
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of combined pulmonary fibrosis and emphysema.
Kitaguchi Y; Fujimoto K; Hanaoka M; Kawakami S; Honda T; Kubo K
Respirology; 2010 Feb; 15(2):265-71. PubMed ID: 20051048
[TBL] [Abstract][Full Text] [Related]
17. Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study.
Maruthur NM; Li M; Halushka MK; Astor BC; Pankow JS; Boerwinkle E; Coresh J; Selvin E; Kao WH
PLoS One; 2015; 10(6):e0128452. PubMed ID: 26083729
[TBL] [Abstract][Full Text] [Related]
18. Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema.
Ando K; Sekiya M; Tobino K; Takahashi K
Lung; 2013 Dec; 191(6):585-91. PubMed ID: 24085320
[TBL] [Abstract][Full Text] [Related]
19. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema.
Zantah M; Dotan Y; Dass C; Zhao H; Marchetti N; Criner GJ
Respir Res; 2020 Jun; 21(1):164. PubMed ID: 32605574
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical characteristics and prognosis of lung cancer patients with CPFE or COPD: a retrospective study.
Wei Y; Yang L; Wang Q
BMC Pulm Med; 2024 Jun; 24(1):274. PubMed ID: 38851701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
